I don't think HLS pulled this off at all. I think there's probably a bigger shoe to drop here whereby Pfizer will be doing this in the U.S. too and it will be announced at a later point. And Amarin is letting it start in Canada, where HLS's tiny sales force has been unable to gain traction.
Amarin knows it's getting poor sales growth in the U.S. and that it's getting harder to use the pandemic as an excuse. It knows it has to do something dramatic to juice sales by the end of this year or people will start grumbling loudly that we're losing revenue that the generics will increasingly steal as their supply grows. It also knows that despite hiring hundreds of additional sales reps, the sales folks still only have time to reach out to cardiologists and doctors who specialize in the treatment of diabetes.
So our best shot is to get a partner who can reach out to general practitioners on a large scale, especially in a country where a surprising number of people are prescribed drugs like Vascepa by their primary care physician.
News 
Market Data 
Discover 
AI
